These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17728024)

  • 1. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.
    Roy S; Kobinger GP; Lin J; Figueredo J; Calcedo R; Kobasa D; Wilson JM
    Vaccine; 2007 Sep; 25(39-40):6845-51. PubMed ID: 17728024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.
    Li Z; Gabbard JD; Mooney A; Gao X; Chen Z; Place RJ; Tompkins SM; He B
    J Virol; 2013 May; 87(10):5985-93. PubMed ID: 23514880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.
    Cheng T; Wang X; Song Y; Tang X; Zhang C; Zhang H; Jin X; Zhou D
    Vaccine; 2016 Sep; 34(41):4875-4883. PubMed ID: 27576071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
    Pandey A; Singh N; Vemula SV; Couëtil L; Katz JM; Donis R; Sambhara S; Mittal SK
    PLoS One; 2012; 7(3):e33428. PubMed ID: 22432020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.
    Vemula SV; Amen O; Katz JM; Donis R; Sambhara S; Mittal SK
    Virus Res; 2013 Dec; 178(2):398-403. PubMed ID: 24051000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.
    Chang H; Huang C; Wu J; Fang F; Zhang W; Wang F; Chen Z
    Virol J; 2010 Aug; 7():197. PubMed ID: 20727202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
    Altenburg AF; Magnusson SE; Bosman F; Stertman L; de Vries RD; Rimmelzwaan GF
    Clin Exp Immunol; 2017 Oct; 190(1):19-28. PubMed ID: 28665497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge.
    Hashem A; Jaentschke B; Gravel C; Tocchi M; Doyle T; Rosu-Myles M; He R; Li X
    Hum Vaccin Immunother; 2012 Apr; 8(4):425-30. PubMed ID: 22370512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
    Gao W; Soloff AC; Lu X; Montecalvo A; Nguyen DC; Matsuoka Y; Robbins PD; Swayne DE; Donis RO; Katz JM; Barratt-Boyes SM; Gambotto A
    J Virol; 2006 Feb; 80(4):1959-64. PubMed ID: 16439551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    Tompkins SM; Zhao ZS; Lo CY; Misplon JA; Liu T; Ye Z; Hogan RJ; Wu Z; Benton KA; Tumpey TM; Epstein SL
    Emerg Infect Dis; 2007 Mar; 13(3):426-35. PubMed ID: 17552096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice.
    Luo M; Qu X; Pan R; Zhu D; Zhang Y; Wu J; Pan Z
    Vaccine; 2011 Mar; 29(14):2561-7. PubMed ID: 21303708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
    Khodamoradi S; Shenagari M; Kheiri MT; Sabahi F; Jamali A; Heidari A; Ashrafkhani B
    Arch Virol; 2018 Apr; 163(4):877-886. PubMed ID: 29270718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.